Prospective validation obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party
[en] Cisplatin doublets are standard 1st line treatment for advanced non-small cell lung
cancer (NSCLC), without accurate predictor for response and survival, but important toxicity.
Our aimswere to identify predictive (for response) and prognostic (for survival) biological
signatures in patients with NSCLC using messenger RNAs (mRNA) and miRNA expression.
Disciplines :
Oncology
Author, co-author :
Berghmans, Thierry
Ameye, Lieveke
Lafitte, Jean-Jacques
Colinet, Benoît
Cortot, Alexis
CsToth, Ingrid
Holbrechts, Stéphane
Lecomte, Jacques
Mascaux, Céline
Meert, Anne-Pascale
Paesmans, Marianne
Richez, Michel
Scherpereel, Arnaud
Tulippe, Christian
Willems, Luc ; Université de Liège > Agronomie, Bio-ingénierie et Chimie (AgroBioChem) > Biologie cell. et moléc.
Prospective validation obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party
Goldstraw P Crowley J Chansky K Giroux DJ Groome PA Rami-Porta R et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol (2007) 2(8):706–14.10.1097/JTO.0b013e31812f3c1a
Sculier JP Chansky K Crowley JJ VanMeerbeeck J Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM classification of malignant tumors and the proposals for the 7th Edition. J Thorac Oncol (2008) 3(5):457–66.10.1097/JTO.0b013e31816de2b818448996
Hou J Aerts J denHamer B vanIjcken W denBakker M Riegman P et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 5(4):e10312.10.1371/journal.pone.001031220421987
NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol (2008) 26(28):4617–25.10.1200/JCO.2008.17.716218678835
Gao G Ren S Li A Xu J Xu Q Su C et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer (2012) 131(5):E822–9.10.1002/ijc.2739622161771
Shaw AT Kim DW Nakagawa K Seto T Crino L Ahn MJ et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 368(25):2385–94.10.1056/NEJMoa121488623724913
Bepler G Williams C Schell MJ Chen W Zheng Z Simon G et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2013) 31(19):2404–12.10.1200/JCO.2012.46.978323690416
Cobo M Isla D Massuti B Montes A Sanchez JM Provencio M et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 25(19):2747–54.10.1200/JCO.2006.09.791517602080
Berghmans T Ameye L Willems L Paesmans M Mascaux C Lafitte JJ et al. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer (2013) 82(2):340–5.10.1016/j.lungcan.2013.07.02024007627
Traitement des cancers bronchiques non à petites cellules: maladies avancées (métastatiques). Recommandations de pratique clinique de l’European Lung Cancer Working Party. Rev Med Brux (2007) 28(6):495–511.
WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: (1979).
Hochberg Y Benjamini Y. More powerful procedures for multiple significance testing. Stat Med (1990) 9(7):811–8.10.1002/sim.47800907102218183
Berghmans T Lafitte JJ Scherpereel A Paesmans M Lecomte J Marco VG et al. An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC. Anticancer Res (2013) 33(12):5477–82.24324084
Treat J Scagliotti GV Peng G Monberg MJ Obasaju CK Socinski MA. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. Lung Cancer (2012) 76(2):222–7.10.1016/j.lungcan.2011.10.02122115704
Ranade AR Cherba D Sridhar S Richardson P Webb C Paripati A et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol (2010) 5(8):1273–8.10.1097/JTO.0b013e3181dea6be20548249
Voortman J Goto A Mendiboure J Sohn JJ Schetter AJ Saito M et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 70(21):8288–98.10.1158/0008-5472.CAN-10-134820978195
Roepman P Jassem J Smit EF Muley T Niklinski J vandeVelde T et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 15(1):284–90.10.1158/1078-0432.CCR-08-125819118056
Ein-Dor L Zuk O Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A (2006) 103(15):5923–8.10.1073/pnas.060123110316585533
Chang JW Wei NC Su HJ Huang JL Chen TC Wu YC et al. Comparison of genomic signatures of non-small cell lung cancer recurrence between two microarray platforms. Anticancer Res (2012) 32(4):1259–65.22493357
Saito M Schetter AJ Mollerup S Kohno T Skaug V Bowman ED et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res (2011) 17(7):1875–82.10.1158/1078-0432.CCR-10-296121350005
Tan X Qin W Zhang L Hang J Li B Zhang C et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res (2011) 17(21):6802–11.10.1158/1078-0432.CCR-11-041921890451
Yanaihara N Caplen N Bowman E Seike M Kumamoto K Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 9(3):189–98.10.1016/j.ccr.2006.01.02516530703
Yu SL Chen HY Chang GC Chen CY Chen HW Singh S et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 13(1):48–57.10.1016/j.ccr.2007.12.00818167339
Boutros PC Lau SK Pintilie M Liu N Shepherd FA Der SD et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A (2009) 106(8):2824–8.10.1073/pnas.080944410619196983
Lau SK Boutros PC Pintilie M Blackhall FH Zhu CQ Strumpf D et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol (2007) 25(35):5562–9.10.1200/JCO.2007.12.035218065728
Sun Z Wigle DA Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol (2008) 26(6):877–83.10.1200/JCO.2007.13.151618281660
Zhu CQ Strumpf D Li CY Li Q Liu N Der S et al. Prognostic gene expression signature for squamous cell carcinoma of lung. Clin Cancer Res (2010) 16(20):5038–47.10.1158/1078-0432.CCR-10-061220739434
Michiels S Koscielny S Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet (2005) 365(9458):488–92.10.1016/S0140-6736(05)17866-015705458
Mascaux C Laes JF Anthoine G Haller A Ninane V Burny A et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J (2009) 33(2):352–9.10.1183/09031936.0008410819010987
Lu Y Lemon W Liu PY Yi Y Morrison C Yang P et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3(12):e467.10.1371/journal.pmed.003046717194181
Soes S Sorensen BS Alsner J Overgaard J Hager H Hansen LL et al. Identification of accurate reference genes for RT-qPCR analysis of formalin-fixed paraffin-embedded tissue from primary non-small cell lung cancers and brain and lymph node metastases. Lung Cancer (2013) 81(2):180–6.10.1016/j.lungcan.2013.04.00723643276
